Hello, Guest!

FDA Approved VEGF Inhibitors

Generic NameBrand NameDosage FormVEGF TargetAdditional TargetsCompanyTickerFDA Approved IndicationsApproval
AfliberceptZaltrapIV InfusionSoluble VEGFPIGFSanofi GenzymeSNYTreatment of patients with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen in combination with fluorouracil, leucovorin, irinotecan (FOLFIRI).Full
AfliberceptEyleaOpthalmic InjectionSoluble VEGFPIGFRegeneronREGNTreatment of Neovascular (wet) Age-Related Macular Degeneration (AMD).Full
AfliberceptEyleaOpthalmic InjectionSoluble VEGFPIGFRegeneronREGNTreatment of Macular Edema following Retinal Vein Occlusion (RVO).Full
AfliberceptEyleaOpthalmic InjectionSoluble VEGFPIGFRegeneronREGNTreatment of Diabetic Macular Edema (DME).Full
AfliberceptEyleaOpthalmic InjectionSoluble VEGFPIGFRegeneronREGNTreatment of Diabetic Retinopathy (DR).Full
AxitinibInlytaOral TabletVEGF ReceptorNonePfizerPFETreatment of advanced renal cell carcinoma after failure of one prior systemic therapy.Full
AxitinibInlytaOral TabletVEGF ReceptorNonePfizerPFEIn combination with pembrolizumab, for the first-line treatment of patients with advanced RCC.Full
AxitinibInlytaOral TabletVEGF ReceptorNonePfizerPFEIn combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC).Full
BevacizumabAvastinIV InfusionSoluble VEGFNoneGenentech (Roche)RHHBYMetastatic colorectal cancer (mCRC), in combination with intravenous fluorouracil based chemotherapy for first- or second-line treatment.Full
BevacizumabAvastinIV InfusionSoluble VEGFNoneGenentech (Roche)RHHBYIn combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, for the second-line treatment of patients with mCRC who have progressed on a first-line Avastin containing regimen.Full
BevacizumabAvastinIV InfusionSoluble VEGFNoneGenentech (Roche)RHHBYIn combination with carboplatin and paclitaxel for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non–squamous non–small cell lung cancer (NSCLC).Full
BevacizumabAvastinIV InfusionSoluble VEGFNoneGenentech (Roche)RHHBYTreatment of recurrent glioblastoma (GBM) in adults.Full
BevacizumabAvastinIV InfusionSoluble VEGFNoneGenentech (Roche)RHHBYIn combination with interferon alfa for the treatment of metastatic renal cell carcinoma (mRCC).Full
BevacizumabAvastinIV InfusionSoluble VEGFNoneGenentech (Roche)RHHBYIn combination with paclitaxel and cisplatin or paclitaxel and topotecan, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer.Full
BevacizumabAvastinIV InfusionSoluble VEGFNoneGenentech (Roche)RHHBYIn combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection.Full
BevacizumabAvastinIV InfusionSoluble VEGFNoneGenentech (Roche)RHHBYIn combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens.Full
BevacizumabAvastinIV InfusionSoluble VEGFNoneGenentech (Roche)RHHBYIn combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.Full
BrolucizumabBeovuOpthalmic InjectionSoluble VEGFNoneNovartisNVSTreatment of Neovascular (Wet) Age-related Macular Degeneration (AMD).Full
CabozantinibCabometyxOral TabletsVEGF ReceptorMET, AXL, RET, ROS1, TYRO3, MER, KIT, TRKB, FLT3, TIE-2ExelixisEXELTreatment of patients with advanced renal cell carcinoma (RCC).Full
CabozantinibCabometyxOral TabletsVEGF ReceptorMET, AXL, RET, ROS1, TYRO3, MER, KIT, TRKB, FLT3, TIE-2ExelixisEXELTreatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.Full
CabozantinibCometriqOral CapsulesVEGF ReceptorMET, AXL, RET, ROS1, TYRO3, MER, KIT, TRKB, FLT3, TIE-2ExelixisEXELTreatment of patients with progressive, metastatic meduallry thyroid cancer (MTC). Full
LenvatinibLenvimaOral CapsulesVEGF ReceptorFGFR, PDGFR, KIT, RETEisaiESALYFor the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).Full
LenvatinibLenvimaOral CapsulesVEGF ReceptorFGFR, PDGFR, KIT, RETEisaiESALYIn combination with everolimus, for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy.Full
LenvatinibLenvimaOral CapsulesVEGF ReceptorFGFR, PDGFR, KIT, RETEisaiESALYFor the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).Full
LenvatinibLenvimaOral CapsulesVEGF ReceptorFGFR, PDGFR, KIT, RETEisaiESALYIn combination with pembrolizumab, for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.Accelerated
PazopanibVotrientOral TabletVEGF ReceptorPDGFR, FGFR, Kit, Itk, Lck, c-FmsNovartisNVSTreatment of patients with advanced renal cell carcinoma (RCC).Full
PazopanibVotrientOral TabletVEGF ReceptorPDGFR, FGFR, Kit, Itk, Lck, c-FmsNovartisNVSTreatment of patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy.Full
PegaptanibMacugenOpthalmic InjectionSoluble VEGFNoneBausch & LombBHCTreatment of neovascular (wet) age-related macular degeneration.Full
RamucirumabCyramzaIV InfusionVEGFR2NoneEli LillyLLYAs a single agent or in combination with paclitaxel, for treatment of advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.Full
RamucirumabCyramzaIV InfusionVEGFR2NoneEli LillyLLYIn combination with docetaxel, for treatment of metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy.Full
RamucirumabCyramzaIV InfusionVEGFR2NoneEli LillyLLYIn combination with FOLFIRI, for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.Full
RamucirumabCyramzaIV InfusionVEGFR2NoneEli LillyLLYAs a single agent, for the treatment of hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib.Full
RanibizumabLucentisOpthalmic InjectionSoluble VEGFNoneGenentech (Roche)RHHBYNeovascular (Wet) Age-Related Macular Degeneration (AMD)Full
RanibizumabLucentisOpthalmic InjectionSoluble VEGFNoneGenentech (Roche)RHHBYMacular Edema Following Retinal Vein Occlusion (RVO)Full
RanibizumabLucentisOpthalmic InjectionSoluble VEGFNoneGenentech (Roche)RHHBYDiabetic Macular Edema (DME) and Diabetic Retinopathy (DR)Full
RanibizumabLucentisOpthalmic InjectionSoluble VEGFNoneGenentech (Roche)RHHBYMyopic Choroidal Neovascularization (mCNV)Full
RegorafenibStivargaOral TabletVEGF ReceptorRET, KIT, PDGFR, FGFR, TIE2, DDR2, TrkA, Eph2A, BRAF, SAPK2, PTK5, Abl, CSF-1RBayerBAYNMetastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy.Full
RegorafenibStivargaOral TabletVEGF ReceptorRET, KIT, PDGFR, FGFR, TIE2, DDR2, TrkA, Eph2A, BRAF, SAPK2, PTK5, Abl, CSF-1RBayerBAYNMetastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy.Full
RegorafenibStivargaOral TabletVEGF ReceptorRET, KIT, PDGFR, FGFR, TIE2, DDR2, TrkA, Eph2A, BRAF, SAPK2, PTK5, Abl, CSF-1RBayerBAYNHepatocellular carcinoma (HCC) who have been previously treated with sorafenib.Full
SorafenibNexavarOral TabletVEGF ReceptorBRAF, KIT, FLT3, RET, PDGFRBayerBAYNUnresectable hepatocellular carcinoma (HCC).Full
SorafenibNexavarOral TabletVEGF ReceptorBRAF, KIT, FLT3, RET, PDGFRBayerBAYNAdvanced renal cell carcinoma (RCC).Full
SorafenibNexavarOral TabletVEGF ReceptorBRAF, KIT, FLT3, RET, PDGFRBayerBAYNLocally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.Full
SunitinibSutentOral TabletVEGF ReceptorPDGFR, KIT, FLT3, CSF-1R, RETPfizerPFEGastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate.Full
SunitinibSutentOral TabletVEGF ReceptorPDGFR, KIT, FLT3, CSF-1R, RETPfizerPFEAdvanced renal cell carcinoma.Full
SunitinibSutentOral TabletVEGF ReceptorPDGFR, KIT, FLT3, CSF-1R, RETPfizerPFEAdjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy.Full
SunitinibSutentOral TabletVEGF ReceptorPDGFR, KIT, FLT3, CSF-1R, RETPfizerPFEProgressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease.Full
VandetanibCaprelsaOral TabletVEGF ReceptorEGFR, RET, BRK, TIE2, EPH, and SrcSanofi GenzymeSNYSymptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.Full

The FDA’s Accelerated Approval program aims to promote earlier approval of drugs to fill an unmet medical need. As such, approval is based on a surrogate endpoint (laboratory measurement, tumor shrinkage, physical sign) that is thought to predict a clinical benefit. Use of surrogate endpoint(s) results in a shorter time in development prior to FDA approval.

If a company receives accelerated approval, they are still required to conduct an additional study to confirm the assumed clinical benefit. If the confirmatory trial shows a clinical benefit, then the FDA will grant traditional (“full”) approval. If the confirmatory trial does not show a clinical benefit, the FDA may elect to remove the drug from the market.

%d bloggers like this: